Pfizer (PFE) Reports FDA Acceptance, Priority Review of Palbociclib NDA
Tweet Send to a Friend
Pfizer (NYSE: PFE) announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE